Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors. Tong Y, Wang F, Li S, Guo W, et al. Hepatology 2024;80:38-54.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tong Y, Wang F, Li S, Guo W, et al. Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors. Hepatology 2024;80:38-54.
PMID: 37556368